Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNA-i-miR-221 Phase I Study in Refractory Multiple Myeloma and Advanced Solid Tumors
NCT04811898Phase 1Completed
- Sponsor
- Azienda Ospedaliera Universitaria Mater Domini
- Start
- Jan 2019
- Primary completion
- Dec 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LNA-i-miR-221 in multiple myeloma (MM) and solid tumor, sponsored by Azienda Ospedaliera Universitaria Mater Domini. Primary endpoints: Safety measured by adverse events at 2 years, Maximum Tolerated Dose at 2 years and 1 more. Started Jan 2019; status: completed.
02
Drugs
LNA-i-miR-221
03
Conditions
multiple myeloma (MM)solid tumor
Beyond the preview
Go deeper on NCT04811898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811898.